Emergent BioSolutions Inc. (EBS), Tuesday announced that the company has secured contract modification from the Biomedical Advanced Research and Development Authority to supply CYFENDUS, a vaccine indicated for post-exposure prophylaxis of anthrax disease.
With the $30 million contract, the company intends to ensure medical countermeasures to protect civilian populations against the threat of anthrax.
Paul Williams, senior vice president, head of products business, global government & public affairs, commented, "We're proud to leverage a U.S.-based supply chain for our anthrax vaccines, as we believe this is critical to Emergent's leadership and continued support of the U.S. government's national security priorities."
In the pre-market hours, EBS is trading at $8.16, down 1.63 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.